Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159614 · ClinicalTrials.gov registry record · Phase 2
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
A Phase 2 study, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00159614 is a Phase 2 study that has completed, run by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 30 participants.
The verdict
NCT00159614, a Phase 2 study, has completed, sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
Interventions
- DRUG KW-3902IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159614
The ClinicalTrials.gov registry entry for NCT00159614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-3902IV is the first listed.
NCT00159614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00159614 about?
NCT00159614 is a clinical study titled "Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment". The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
What is the current status of trial NCT00159614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-09.
What interventions are being tested in trial NCT00159614?
The interventions under investigation include: KW-3902IV (DRUG).
Who is sponsoring clinical trial NCT00159614?
This trial is sponsored by NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.